Skip to main content
Publications
Phillips T, Lugtenburg P, Kalsekar A, Mutebi A, Wang A, Blaedel J, Kosa K, Martin S, Sacchi M, Kilavuz N, Thieblemont C. Improvements in patient-reported outcomes in relapsed or refractory large b-cell lymphoma patients treated with epcoritamab. Clin Lymphoma Myeloma Leuk. 2023 Nov 27;24(3):e78-e87.e. doi: 10.1016/j.clml.2023.11.005
Cohen AD, Hari P, Htut M, Berdeja JG, Usmani SZ, Madduri D, Olyslager Y, Goldberg JD, Schecter JM, Jackson CC, Gries KS, Fastenau JM, Valluri S, Deraedt W, Akram M, Crawford R, Morrison R, Doward L, Morgan K, Seldam ST, Jakubowiak A, Jagannath S. Patient perceptions regarding ciltacabtagene autoleucel treatment: qualitative evidence from interviews with patients with relapsed/refractory multiple Myeloma in the CARTITUDE-1 study. Clin Lymphoma Myeloma Leuk. 2022 Nov 7;16:54. doi: /10.1016/j.clml.2022.10.001
Spira A, Zhou X, Chen L, Gnanasakthy A, Wang L, Ungar D, Curiel R, Liao L, Radford J, Kahl B. Health-related quality of life, symptoms, and tolerability of Loncastuximab Tesirine in patients with relapsed or refractory diffuse large b-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):158-68. doi: 10.1016/j.clml.2021.09.001
Police RL, Trask PC, Wang J, Olivares R, Khan SB, Abbe A, Colosia AD, Njue AI, Sherrill EH, Ruiz-Soto R, Kaye JA, Hamadani M. Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):199-207. doi: 10.1016/j.clml.2014.09.008
Njue A, Colosia A, Trask PC, Olivares R, Khan S, Police R, Abbe A, Wang J, Kaye JA, Ruiz-Soto R, Awan F. Clinical efficacy and safety in relapsed/refractory mantle cell lymphoma: a systematic literature review. Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):1-12. doi: 10.1016/j.clml.2014.03.006
Colosia A, Njue A, Trask PC, Olivares R, Khan S, Abbe A, Police R, Wang J, Ruiz-Soto R, Kaye JA, Awan F. Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review. Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):343-55. doi: 10.1016/j.clml.2014.02.012
Prescott G, Sharp P, Goatman K, Scotland G, Fleming A, Philip S, Staff R, Santiago C, Borooah S, Broadbent D, Chong V, Dodson P, Harding S, Leese G, Megaw R, Styles C, Swa K, Wharton H, Olson J. Improving the cost-effectiveness of photographic screening for diabetic macular oedema: a prospective, multi-centre, UK study. Br J Ophthalmol. 2014 Aug 1;98(8):1042-9. doi: 10.1136/bjophthalmol-2013-304338
Oldenburg CE, Sy A, Srinivasan M, Toutain-Kidd CM, Mascarenhas J, Ravindran M, Rajaraman R, Esterberg EJ, Chidambaram JD, Acharya NR, Lietman TM, Zegans ME. Pre-existing blindness in a cohort of patients with bacterial keratitis. Br J Ophthalmol. 2011 Dec;95(11):1612-3. doi: 10.1136/bjophthalmol-2011-300270.
Fleming AD, Goatman KA, Philip S, Williams GJ, Prescott GJ, Scotland GS, McNamee P, Leese GP, Wykes WN, Sharp PF, Olson JA. The role of haemorrhage and exudate detection in automated grading of diabetic retinopathy. Br J Ophthalmol. 2010 Jun 1;94(6):706-11. doi: 10.1136/bjo.2008.149807
Scotland GS, McNamee P, Fleming AD, Goatman KA, Philip S, Prescott GJ, Sharp PF, Williams GJ, Wykes E, Leese GP, Olson JA. Costs and consequences of automated algorithms versus manual grading for the detection of referable diabetic retinopathy. Br J Ophthalmol. 2010 Jun 1;94(6):712-9. doi: 10.1136/bjo.2008.151126.